FANCE
Summary: The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group E. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| FA complementation group E | MIM:613976 | Ensembl:ENSG00000112039 | HGNC:HGNC:3586 | PA28000 | 6p21.31 |
GO terms in FANCE
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| CC | NAS | GO:0005634 | nucleus |
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IDA | GO:0043240 | Fanconi anaemia nuclear complex |
| BP | TAS | GO:0036297 | interstrand cross-link repair |
| MF | ND | GO:0003674 | molecular_function |
| MF | IPI | GO:0005515 | protein binding |
Gene expression in normal tissue: FANCE
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in FANCE
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| biocarta | atrbrcapathway | role of brca1 brca2 and atr in cancer susceptibility |
| biocarta | bard1pathway | brca1 dependent ub ligase activity |
| reactome | R-HSA-6783310 | Fanconi Anemia Pathway |
| reactome | R-HSA-73894 | DNA Repair |
| pid | bard1pathway | BARD1 signaling events |
| pid | fanconi_pathway | Fanconi anemia pathway |
| kegg | hsa03460 | Fanconi anemia pathway - Homo sapiens (human) |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD599 | Salermide | 4 |
| iGMDRD420 | Leucascandrolide A | 2 |
| iGMDRD554 | CHEMBL1434137 | 4 |
| iGMDRD210 | AC55649 | 2 |
| iGMDRD433 | Lexibulin | 1 |
| iGMDRD151 | CHM-1 | 2 |
| iGMDRD494 | Neopeltolide | 3 |
| iGMDRD781 | Sirolimus | 6 |
| iGMDRD427 | ABT737 | 2 |
| iGMDRD546 | BMS-754807 | 2 |
| iGMDRD193 | Fqi1 | 1 |
| iGMDRD634 | SCHEMBL2608041 | 2 |
| iGMDRD679 | Bistramide A | 2 |
| iGMDRD802 | 4-methylfasudil | 2 |
| iGMDRD260 | FQI-2 | 2 |
| iGMDRD134 | Sorafenib | 2 |
| iGMDRD138 | PX 12 | 3 |
| iGMDRD318 | PAC-1 | 3 |
| iGMDRD226 | ML006 | 1 |
| iGMDRD870 | BRD63610 | 1 |
| iGMDRD782 | DC-45-A2 | 1 |
| iGMDRD888 | Compound 44 | 1 |
| iGMDRD577 | BIX01294 | 7 |
| iGMDRD780 | PP-30 | 4 |
| iGMDRD690 | PRIMA-1MET | 2 |
| iGMDRD64 | Parbendazole | 2 |
| iGMDRD60 | Quinoclamine | 2 |
| iGMDRD248 | BRD4354 | 1 |
| iGMDRD79 | Gemcitabine | 2 |
| iGMDRD424 | Tamatinib | 2 |
| iGMDRD351 | GW843682X | 1 |
| iGMDRD57 | Chloropentafluorobenzene | 1 |
| iGMDRD945 | ML214 | 2 |
| iGMDRD154 | NSC23766 | 5 |
| iGMDRD177 | Teniposide | 5 |
| iGMDRD103 | SN-38 | 2 |
| iGMDRD158 | NSC141540 | 5 |
| iGMDRD271 | Brefeldin A | 2 |
| iGMDRD68 | Paclitaxel | 2 |
| iGMDRD105 | Triptolide | 4 |
| iGMDRD6 | AM-580 | 2 |
| iGMDRD329 | Merck60 | 2 |
| iGMDRD871 | BRD6368 | 1 |
| iGMDRD286 | Nsc 632839 | 1 |
| iGMDRD872 | BRD7137 | 3 |
| iGMDRD882 | CIL41 | 2 |
| iGMDRD82 | Quiflapon | 2 |
| iGMDRD886 | Compound 1541A | 2 |
| iGMDRD246 | NPC26 | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in FANCE
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.